Funding Cuts Threaten Cancer Immunotherapies
Researcher Miriam Merad warns that NIH funding cuts could hinder life-saving cancer research, particularly in the development of new immune cell-based therapies.
Macrophages, known as the body's "guardians," play a crucial role in detecting and clearing damage from organs and tissues. However, they can also weaken inflammation, undermining immune cells that attack tumor cells.
By weakening inflammation, they can undermine immune cells that attack tumor cells.
Oncologist Miriam Merad is dedicated to understanding how to adapt the powers of immune cells, including T cells and macrophages, to improve current immunotherapies. The scientific challenge is significant, and funding cuts are a major concern.
- 40% of National Institutes of Health grant dollars are being cut.
- These cuts pose a threat to the development of new cancer immunotherapies.
Miriam Merad, director of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai, emphasizes the need for continued research funding to advance cancer treatment.
Author's summary: Funding cuts jeopardize cancer research progress.
More News
- Why I still love newspapers
- Lane closures as works carried out along Pacific Highway
- Romance scammers stole £428k from lonely Brit – the red flags most miss
- CTA proposes first fare hike in seven years: here’s by how much
- Mamdani, Cuomo, Sliwa Meet in First General-Election Debate: Live Updates
- Proportion of care workers with basic qualifications hits new low following training cuts, shows report - Community Care
- COLUMN: Bahamas getting the US Ambassador we need
- Nuclear Stocks Sell Off After U.S. Army Launches Microreactor Program | OilPrice.com
- LeBron XXIII “The Chosen One and The One Who Chose” Celebrates Basketball’s Most Historic Father–Son Moment
- SpaceX gets ready for overnight Starlink launch